Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mansoura Univ. EGFR/HER-2 compound 23: sourced facts only. name: "Compounds 23 and 39 were identified as possible EGFR, HER-2, and DHFR inhibitors."; target: "Compounds 23 and 39 were identified as possible EGFR, HER-2, and DHFR inhibitors."; target: "Compounds 23 and 39 were identified as possible EGFR, HER-2, and DHFR inhibitors."; target: "Compounds 23 and 39 were identified as possible EGFR, HER-2, and DHFR inhibitors."; developer: "Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, 35516 Mansoura, Egypt."; stage: "Compounds 23 and 39 exhibited potent activity against the MCF-7 breast cancer cell line, with IC50 values of 1.81 and 4.95 μM, respectively, compared to DOX and SOR (IC50 values of 4.17 and 7.26 μM, respectively)."
Source types: Peer-reviewed publication. Sources are available to Gosset users. Log in to see them.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Mansoura Univ. EGFR/HER-2 compound 23.
Work on Mansoura Univ. EGFR/HER-2 compound 23? Claim this page to correct or add information. Claim this page